- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FDA Approves First Treatment to Reduce Mortality in Infantile-Onset Niemann-Pick Disease Type C

The US FDA has approved Lembaz (adrabetadex) injection, the first treatment demonstrated to help patients with severe Niemann-Pick disease type C (NPC) live longer.
Approved to reduce the risk of death in adults and children weighing at least 7 kg (15 pounds). Indicated for patients whose neurological symptoms began before 6 years of age (infantile-onset NPC).
This approval marks a significant advance in the treatment of this rare, progressive and life-threatening genetic disorder.
“For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” said Acting FDA Commissioner Kyle Diamantas, J.D. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”
Niemann-Pick disease type C (NPC) is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which the body cannot properly process cholesterol and other fats inside cells. Over time, these substances accumulate — particularly in the brain — causing progressive neurological decline, including loss of movement, coordination, and the ability to swallow. Patients whose neurological symptoms begin before age 6 face the most serious form of the disease.
Prior to this approval action, two therapies were approved for NPC, but neither has been shown to reduce the risk of death. Both carry age and weight restrictions that limit access for the youngest and most seriously affected patients. Lembaz is the first FDA-approved therapy to reduce the risk of death in adults and children weighing at least 7 kg (about 15 pounds) with NPC whose neurological symptoms began before age 6. A trained healthcare provider gives Lembaz as an injection directly into the spinal canal — a procedure called an intrathecal injection — every two weeks.
To assess whether Lembaz reduced the risk of death, the FDA examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program. All patients had neurological manifestations of NPC that occurred prior to age 6. Patients treated with Lembaz had longer overall survival compared to the matched external control group, with a 55% reduction in the risk of death. The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group. This survival benefit was observed regardless of whether patients were also taking miglustat, a therapy used off-label in NPC.
The most common side effects of Lembaz include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. A comprehensive hearing evaluation should be performed on patients before starting Lembaz and regularly throughout treatment, and dose adjustments may be needed based on the results of these evaluations.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

